NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET FORECAST 2019-2027

NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET FORECAST 2019-2027

  • February 2019 •
  • 112 pages •
  • Report ID: 5743546 •
  • Format: PDF
KEY FINDINGS
The North American region is one the largest antidepressants drugs, devices, and therapies by diagnosed patients, devices manufacturers and establishment of several psychiatrists and psychologists that have contributed to the growth of the market at a CAGR of 1.27% during the forecasting years of 2019-2027.

MARKET INSIGHTS
The regional market study of North America covers the analysis of the United States and Canada economy, which further reveals that North America reaps the highest amount of revenue among other regions for antidepressants drugs, devices, and therapies market.The region is known to include the United States which has the highest number of patients diagnosed with clinical depression.

The US market for antidepressants drugs, devices, and therapies driven by strict regulatory implications. Establishment of generic drug makers in the market poses a great challenge for the branded manufacturers as the loss of patents is a regular occurrence in the market.

COMPETITIVE INSIGHTS
Some of the competing antidepressants drug manufacturing market players are Brainsway, F. Hoffmann-La Roche Ltd., Neuronetics, Allergan PLC, Boehringer Ingelheim GmbH, Eli Lilly and Company, H. Lundbeck AS, GlaxoSmithKline, Pfizer, Mayo Clinic and Abbot Laboratories.

Companies mentioned
1. ABBOT LABORATORIES
2. ALLERGAN PLC
3. BOEHRINGER INGELHEIM GMBH
4. BRAINSWAY
5. ELI LILLY AND COMPANY
6. F. HOFFMANN-LA ROCHE LTD.
7. GLAXOSMITHKLINE
8. H. LUNDBECK AS
9. MAYO CLINIC
10. NEURONETICS
11. PFIZER